top of page

New Amsterdam Pharma is trying to revive the CETP class for cardiovascular disease

CEO Michael Davidson describes how Obicetrapib, which was reacquired from Amgen, is designed to produce more LDL lowering than other assets in the class.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page